Table 1.
Rodent Models | Pharmacological Intervention or Genetic Manipulation |
Route of Administration/ Region |
Direction of Behavioral Effect |
Reference |
---|---|---|---|---|
Anxiety-like Behavior | NPY | i.c.v. BLA, CeA Hippocampus Lateral Septum LC |
Decrease | [67–70] [73–75] [71, 72] [77] [76] |
NPY knockout | Increase | [65] | ||
Y1R agonists | i.c.v. CeA Hippocampus |
Decrease | [69, 86] [75, 88] [87] |
|
Y1R antagonists | i.c.v. PAG LC Hypothalamus CeA |
Increase No effect |
[89–91] [89] |
|
Y1R knockout | Increase | [83–85] | ||
Y2R agonist | i.c.v. LC Lateral septum BLA (high dose) |
No effect Decrease |
[67–69, 86] [76] [94] [96] |
|
Y2R antagonists | CeA | Decrease | [98] | |
Y2R knockout | Global, BLA or CeA GABAergic neurons in CeA |
Decrease Increase |
[99–103] [97] |
|
Y4R knockout | Decrease | [100, 102] | ||
Y5R agonist | i.c.v. | Decrease | [86] | |
Y5R antagonist | BLA | Decrease | [105] | |
Arousal | NPY | i.c.v., BLA CeA |
Decrease No effect |
[67, 92, 110] [110] |
NPY knockout | Increase | [66] | ||
Y1R agonists | i.c.v. | Decrease | [67] | |
Y2R | i.c.v. | No effect | [67] | |
Y2R knockout | Increase | [66] | ||
Fear | NPY | i.c.v., Amygdala | Decrease | [110, 116–118] |
NPY knockout | Increase | [119] | ||
Y1R agonists | i.c.v. | Decrease | [116] | |
Y1R antagonists | i.c.v. Amygdala |
Block NPY effects Increase |
[116] [110] |
|
Y1R knockout | Increase | [117] | ||
Y2R knockout | No effect | [119] | ||
Depression-like Behavior | NPY | i.c.v., Hippocampus | Decrease | [122–125] |
Y1R agonists | i.c.v. | Decrease | [124] | |
Y1R antagonists | i.c.v. | Block NPY effects | [124] | |
Y1R knockout | Increase | [81] | ||
Y2R antagonists | i.c.v. | Decrease | [124] | |
Y2R knockout | Decrease | [101] | ||
Y4R knockout | Decrease | [100, 102] | ||
Depression Models (OBX or FSL) |
NPY | Decrease (OBX) | [139] | |
Y1R agonist | i.c.v. | Decrease (OBX) | [139] | |
Y2R agonist | i.c.v. | Increase (OBX) | [141] | |
Y2R antagonist | i.c.v. | Decrease (OBX) | [140] | |
Y5R antagonist | i.c.v. | Decrease (FSL) | [134] | |
PTSD models (PSS and SPS) |
NPY | Intranasal, Hippocampus |
Decrease anxiety, arousal, fear, depression-like behaviors |
[147, 149, 151] |
Y1R antagonist | Hippocampus | Increase anxiety, arousal |
[147] |